Document:

Exhibit 10.2

 

EMPLOYMENT
AGREEMENT

 

THIS
EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Odyssey Group International Inc. (the
“Company”) a Nevada Corporation and Christine Farrell (the “Executive”) whose address is
23586 NW St. Helens Rd. U-82, Portland, OR 97231.

 

WHEREAS,
the Company desires to continue employing the Executive as its Chief Financial Officer and the Executive desires to continue serving
in such capacity on behalf of the Company.

 

WHEREAS,
the Company and the Executive desire to enter into this Agreement to set forth the terms and conditions of the employment relationship
between the Company and the Executive;

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements contained herein, and other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

 

1.       Employment.

 

(a)
       Term. Executive’s Term of employment (the “Term”) under
this Agreement shall be three (3) years, commencing on January 1, 2021 (the “Effective Date”), and shall continue
for a period through and including January 1 2024 (the “Initial Term”), provided that on the third (3rd)
anniversary of the Effective Date and each subsequent one (1) year anniversary of the Effective Date, the Term of the Executive’s
employment hereunder will be automatically extended for an additional period of one (1) year (each a “Subsequent Term”)
unless either the Executive or the Company has given written notice to the other that such automatic extension will not occur
(a “Non-Renewal Notice”), which notice was given not less than one hundred twenty (120) days prior to the relevant
anniversary of the Effective Date. The Initial Term and any Subsequent Term are referred to herein as the “Term.”
If the Company gives a Non-Renewal Notice then it will be considered a termination without Cause per Section 6 of this Agreement.

 

(b)       Duties.
During the Term, the Executive shall serve as the Chief Financial Officer or other job related to the Company’s financials
of the Company with duties, responsibilities and authority commensurate therewith and shall report to the Chief Executive Officer
or his designee (the “CEO”). The Executive shall perform all duties and accept all responsibilities incident
to such position as may be reasonably assigned by the CEO. The Executive represents to the Company that she is not subject to
or a party to any other employment agreement, non-competition covenant, or other agreement that would be breached by, or prohibit
the Executive from executing, this Agreement and performing fully her duties and responsibilities under this Agreement.

 

(c)       Exclusive
Services. Subject to the permissions and restrictions specified in Section 14 below, Executive agrees to devote her energies
and skill to the discharge of the duties and responsibilities attributable to her position, and to this end will devote her full
business time and attention to the business and affairs of the Company and its affiliated entities. The foregoing shall not be
construed as preventing the Executive from (1) serving on civic, trade association, industry, educational, philanthropic, charitable
or non-profit boards or committees, or, on corporate boards for businesses that are not in competition with the Company, and (2)
managing personal investments, so long as such activities do not conflict with the Company’s published code of conduct and
employment policies.

 

(d)       Principal
Place of Employment. The Executive understands and agrees that her Principal Place of Employment will be in the Executive’s
residence and that she will be required to travel for business in the course of performing her duties for the Company. The Company
understands and agrees that the Executive plans to retain her principal residence in the State of Oregon but may change residency
at any time.

 

 

 

 

    	 	1	 

     

    

 

2.       Compensation.

 

(a)       Base
Salary and Accrued compensation. During the Employment Term, the Company shall pay the Executive a minimum annual base salary
of $120,000 (“Base Salary”) payable in equal installments at such payment intervals as are the usual custom
of the Company, but not less often than monthly. Base salary will be $200,000 when the Company has raised a cumulative of $5,000,000
in funding. Thereafter the Base Salary will be reviewed and may be adjusted no less frequently than annually.

 

(b)       Annual
Bonus. The Executive shall be eligible to receive a bonus for each calendar year during
the Term, of between up to twenty percent (20%) of Base Salary, commencing with the 2021 calendar year, based on the attainment
of individual and corporate performance goals and targets established by the Board in its sole discretion after consultation with
the Executive by January 31st of each calendar year (“Annual Bonus”); provided, however, that the
amount, if any, and timing of such bonus shall be determined by the Company but paid no later than forty-five (45) days after
the calendar year end. The Annual Bonus shall be subject to the terms of the annual bonus plan that is applicable to other executives
of the Company, including requirements as to continued employment, subject to the provisions of Section 6 below. 

 

(c)       Equity
Incentive. Executive will be granted Restricted Stock Units (RSU’s) in the amount of one million (1,000,000) RSU’s
(or stock options at the Executive’s choosing),vesting equally over 36 months.

 

In
the event of a Change of Control (as defined in this Section 2(c)) of the Company while you continue to be employed by the Company,
any RSU’s or stock options will become fully vested and exercisable. For purposes of this Agreement, a “Change
of Control” means that any of the following events has occurred:

 

(i)       Any
person or entity (as such term is used in Section 13(d) of the Securities Exchange Act of 1934 (the “Exchange Act”)),
other than the Company, any employee benefit plan of the Company or any entity organized, appointed or established by the Company
for or pursuant to the terms of any such plan, together with all “affiliates” and “associates” (as such
terms are defined in Rule 12b-2 under the Exchange Act) becomes the beneficial owner or owners (as defined in Rule 13d-3 and 13d-5
promulgated under the Exchange Act), directly or indirectly (the “Control Group”), of more than 50% of the
outstanding equity securities of the Company, or otherwise becomes entitled, directly or indirectly, to vote more than 50% of
the voting power entitled to be cast at elections for directors (“Voting Power”) of the Company;

 

(ii)       A
consolidation or merger (in one transaction or a series of related transactions) of the Company pursuant to which the holders
of the Company’s equity securities immediately prior to such transaction or series of related transactions would not be
the holders, directly or indirectly, immediately after such transaction or series of related transactions of more than 50% of
the Voting Power of the entity surviving such transaction or series of related transactions;

 

(iii)       The
sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all or substantially all of
the assets of the Company; or

 

(iv)       The
liquidation or dissolution of the Company or the Company ceasing to do business.

 

 

 

 

    	 	2	 

     

    

 

3.       Benefit
Plans. During the Employment Term, and as otherwise provided herein, Executive shall be entitled to participate in any and
all employee welfare and health benefit plans (including, but not limited to, life insurance, health, dental, and disability plans)
and other employee benefit plans, including, but not limited to, qualified pension plans, established by the Company from time-to-time
for the benefit of all executives of the Company. Executive shall be required to comply with the conditions attendant to coverage
by such plans and shall comply with and be entitled to benefits only in accordance with the terms and conditions of such plans
as they may be amended from time-to-time. Nothing contained in this Agreement shall be construed as requiring the Company to establish
or continue any particular benefit plan in discharge of its obligations under this Agreement or preclude the Company or any affiliate
of the Company from terminating or amending any employee benefit plan or program from time-to-time after the Effective Date.

 

4.       Vacation.
During the Term, the Executive shall be entitled to five (5) weeks of paid vacation each year and holiday and sick leave at
levels commensurate with those provided to other senior executive officers of the Company, in accordance with the Company’s
vacation, holiday and other pay for time not worked policies.

 

5.       Expenses.
The Company shall pay or reimburse the Executive for all reasonable, ordinary, and necessary business expenses incurred by
the Executive in the performance of her responsibilities and the promotion of the Company’s businesses, including, without
limitation, air travel and lodging, automobile and related expenses, cellular phone charges, and travel expenses of the Executive’s
spouse when accompanying him on business-related trips. The Executive shall submit to the Company periodic statements of all expenses
so incurred. Subject to such reasonable accounting procedures as the Company may adopt generally from time-to-time for executives,
the Company shall reimburse the Executive the full amount of any such expenses advanced by him in the ordinary course of business.
The Company shall reimburse the Executive for travel to/from the Principal Place of Employment including
food and lodging, together with reasonable dues and related expenses for industry associations and groups, publications,
required professional training and similar activities. All such reimbursement of expenses shall be paid within fifteen
(15) days of submitting receipts for such expenses.

 

6.       Termination
without Cause: Resignation for Good Reason. The Company may terminate the Executive’s employment at any time without
Cause. In addition, the Executive may initiate a termination of employment by resigning for Good Reason. Upon termination by the
Company without Cause or resignation by the Executive for Good Reason, the Executive shall be entitled to receive, in lieu of
any payments under any severance plan or program for employees or executives, the following:

 

(a)       For the greater of the time remaining in the Term and the 6-month period following the Executive’s termination date
(the “Severance Period”), the Company will pay the Executive an amount equal to the sum of (x) the Executive’s
annual Base Salary payable over the Severance Period in equal installments in accordance with the Company’s regular payroll
practices, plus (y) eighty (80) percent of the Executive’s Annual Bonus only for the calendar year in which termination
occurs, which shall be paid at the same time as other executive bonuses are paid but no later than as required by Code §
409A.

 

(b)       Any unvested portion of RSU’s or Option granted under Section 2(c) or any other time during Executive’s employment,
will vest immediately.

 

(c)       The Company will pay any other amounts earned, accrued and owing but not yet paid under Section 2 above and any benefits
accrued and due under any applicable benefit plans and programs of the Company, regardless of whether the Executive executes or
revokes the Release. The Company shall continue to pay for Executive’s health and dental coverage, if applicable, for the
shorter of the Severance Period or the maximum period permissible under COBRA.

 

 

 

 

    	 	3	 

     

    

 

(d)       The Company will assign all right, title and ownership to any life insurance policies maintained on the life of Executive
to Executive for no additional consideration, other than the Executive’s agreement to continue making premium payments on
such policies if the Executive desires to keep such policies in full force and effect.

 

7.       Termination
with Cause. The Company may terminate the Executive’s employment at any time for Cause (as defined below) upon ninety
days written notice to the Executive and an opportunity to cure such Cause within sixty days of the written notice. If Executive
is unable to cure the Cause then all payments under this Agreement shall cease, except for any amounts earned, accrued and owing
but not yet paid under Section 2 above and any benefits accrued and due under any applicable benefit plans and programs of the
Company.

 

8.       Voluntary
Resignation without Good Reason. The Executive may voluntarily terminate employment without Good Reason for any reason upon
30 days prior written notice to the Company. In such event, after the Effective Date of such termination, no payments shall be
due under this Agreement, except that the Executive shall be entitled to any amounts earned, accrued and owing but not yet paid
under Section 2 above, any benefits accrued and due under any applicable benefit plans and programs of the Company, and any unvested
portion of the Option granted under Section 2(c) will vest immediately, or any lapsing repurchase right on shares of common stock
acquired upon the exercise of the Option shall lapse.

 

9.       Disability.
If, during the Term, Executive is or becomes Disabled, the Company may, upon at least ten (10) days’ prior written notice
given at any time after Executive is determined to be Disabled, notify Executive of its intention to terminate this Agreement
as of the date set forth in the notice. In case of such termination, Executive shall be entitled to receive salary, benefits,
and reimbursable expenses owing to Executive through the date of termination. The Company shall have no further obligation or
liability to Executive; provided, however, that notwithstanding the foregoing provisions of this Section 9, if Company has in
place a long-term disability plan that covers Executive, then the Executive shall be eligible to receive such long-term disability
benefits under the Company’s long-term disability plan to which she is otherwise entitled under the plan. For purposes hereof,
“Disability” shall mean either (a) the Executive is deemed Disabled for purposes of any group or individual
long-term disability policy paid for by the Company and in effect at the time of such determination, or (b) if, in the good faith
judgment of the Board, as certified by a physician reasonably satisfactory to the Executive or her legal representative and the
Board (provided, however, that in the event the Board and such individual (or her or her legal representative) cannot
agree on the selection of a physician, the Executive’s selection shall prevail), the Executive is substantially unable to
perform the Executive’s duties under this Agreement for a period of four (4) or more consecutive months, or for a total
period of six (6) months in any twelve-consecutive month period, by reason of a physical or mental illness or injury.

 

10.       
Death.

 

(a)
If the Executive dies during the Term, the Executive’s employment shall terminate on the date of death and the Company shall
pay to the Executive’s executor, legal representative, administrator or designated beneficiary, as applicable, any amounts
earned, accrued and owing but not yet paid under Section 2 above and any benefits accrued and due under any applicable benefit
plans and programs of the Company, including with respect to the Option or shares acquired upon exercise thereof.

 

(b)
Executive acknowledges that her services are of substantial economic importance to the Company and that her death may cause result
in substantial economic loss to the Company. To mitigate against that loss, Executive acknowledges and agrees that Company at
its expense may obtain one or more policies of life insurance on Executive’s life, and that the Company, or such other persons
as may be designated by Company, may be named in Company’s sole and absolute discretion as the beneficiary(ies) of the proceeds
payable under the insurance policy upon Executive’s death or as otherwise payable under the policy. Executive for himself,
her executors, administrators, heirs, and assigns waives any claim or entitlement for any benefit or payment under any policy
of insurance obtained by the Company, except as expressly stated to the contrary in a written instrument signed by a duly authorized
officer of the Company other than Executive.

 

 

 

 

    	 	4	 

     

    

 

11.       Resignation
of Positions. Effective as of the date of any termination of employment, the Executive will resign all Company-related positions,
including as an officer of the Company and its parents, subsidiaries and affiliates. If the Executive continues owning shares
of capital stock of the Company in excess of ten percent (10%) of the total issued and outstanding shares of the Company following
termination of employment, the Executive may remain as a member of the Company’s Board of Directors.

 

12.       Definitions.
For purposes of this Agreement, the following terms shall have the following meanings:

 

(a)       “Cause”
shall mean:

 

(1)       Executive
pleads “guilty” to or is convicted of any act that is defined as a felony under federal or state law, in connection
with the performance of Executive’s obligations to the Company and materially and adversely affects Executive’s ability
to perform such obligations;

 

(2)       The commission and conviction by Executive of an act of fraud or embezzlement against the Company, as determined by a court of
competent jurisdiction;

 

(b)       “Good
Reason” shall mean the occurrence of one or more of the following without the Executive’s consent:

 

(1)       the material breach by the Company of this Agreement;

 

(2)       the reduction of more than twenty percent by the Company of the Base Salary in effect on the Effective Date or as the
same may be increased from time-to-time, without the Executive’s consent;

 

(3)       any failure by the Company to reappoint the Executive to a position held by the Executive on the date of a Change in
Control (as defined in Section 2(c)), except as a result of the termination of the Executive’s employment by the Company
for Cause or Disability, the death of the Executive, or the termination of the Executive’s employment by the Executive other
than for Good Reason;

 

(4)       elimination by the Company of the Option or other equity-based compensation plan, without providing substantially equivalent
substitutes therefor;

 

(5)       the taking of any action by the Company (including the elimination of benefit plans without providing substitutes
therefor or the reduction of the Executive’s benefits thereunder) that would substantially diminish the aggregate value
of the Executive’s other fringe benefits;

 

(6)       the Company provides written notice to the Executive that the Executive will be required to move her principal residence
to remain in her position as Chief Financial Officer; and

 

(7)       any failure by the Company to require any successor entity (whether direct or indirect, by purchase, merger, consolidation
or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform
this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession
had taken place.

 

The
Executive must provide written notice of termination for Good Reason to the Company within 30 days after the event constituting
Good Reason. The Company shall have a period of 30 days in which it may correct the act or failure to act that constitutes the
grounds for Good Reason as set forth in the Executive’s notice of termination. If the Company does not correct the act or
failure to act, the Executive’s employment will terminate for Good Reason on the first business day following the Company’s
30-day cure period.

 

 

 

 

    	 	5	 

     

    

 

(c)       “Release”
shall mean a separation agreement and mutual general release, in a form provided by the Company and agreed to by Executive, of
any and all claims against the Company and Executive, all related parties with respect to all matters arising out of the Executive’s
employment by the Company, and the termination thereof (other than claims for any entitlements under the terms of this Agreement
or under any plans or programs of the Company under which the Executive has accrued and is due a benefit).

 

13.       Section
409A.

 

(a)       This Agreement is intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”)
and its corresponding regulations, or an exemption, and payments may only be made under this Agreement upon an event and in a
manner permitted by Code § 409A of the Code, to the extent applicable. Severance benefits under the Agreement are intended
to be exempt from Code § 409A under the “short-term deferral” exception, to the maximum extent applicable, and
then under the “separation pay” exception, to the maximum extent applicable. Notwithstanding anything in this Agreement
to the contrary, if required by Code § 409A, if the Executive is considered a “specified employee” for purposes
of Code § 409A and if payment of any amounts under this Agreement is required to be delayed for a period of six months after
separation from service pursuant to Code § 409A, payment of such amounts shall be delayed as required by Code § 409A,
and the accumulated amounts shall be paid in a lump-sum payment within ten days after the end of the six-month period. If the
Executive dies during the postponement period prior to the payment of benefits, the amounts withheld on account of Code §
409A shall be paid to the personal representative of the Executive’s estate within 60 days after the date of the Executive’s
death.

 

(b)       All payments to be made upon a termination of employment under this Agreement may only be made upon a “separation
from service” under Code § 409A. For purposes of Code § 409A, each payment hereunder shall be treated as a separate
payment and the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate
payments. In no event may the Executive, directly or indirectly, designate the calendar year of a payment. Notwithstanding any
provision of this Agreement to the contrary, in no event shall the timing of the Executive’s execution of the Release, directly
or indirectly, result in the Executive designating the calendar year of payment of any amounts of deferred compensation subject
to Code § 409A, and if a payment that is subject to execution of the Release could be made in more than one taxable year,
payment shall be made in the later taxable year.

 

(c)       All reimbursements and in-kind benefits provided under the Agreement shall be made or provided in accordance with the requirements
of Code § 409A, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during the
period of time specified in this Agreement, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided,
during a calendar year may not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other
calendar year, (iii) the reimbursement of an eligible expense will be made no later than the last day of the calendar year following
the year in which the expense is incurred, and (iv) the right to reimbursement or in-kind benefits is not subject to liquidation
or exchange for another benefit.

 

14.       Restrictive
Covenants. Executive acknowledges that her position with the Company is special, unique, and intellectual in character, that
in her position she will have special access to and knowledge about Company plans, strategies, intellectual property including
trade secrets and know-how, and that her position in the Company will place him in a position of confidence and trust with employees
and clients of the Company. For this reason, Executive agrees that the provisions set forth below in this Section 14 are fair
and reasonable to the Company, its shareholders, and the Executive.

 

(a)       Non-Competition. During the Term and during the Severance Period (the “Restriction Period”),
the Executive hereby agrees that the Executive will not, without the Board’s express written consent, (directly or indirectly),
act as a director or officer of a Competitive Business where Executive would be required to use, contribute or disclose Executive’s
knowledge of the business operations, plans or strategies of the Company to such Competitive Business. The term “Competitive
Business” means a business engaged in the United States in designing, developing, producing, marketing, licensing and/or
selling a device utilizing the issued patent relating to the CardioMap device owned by the Company or a device that utilizes the
patents owned by Company for a choking rescue device. For purposes of this Agreement, the term “Affiliate”
means any subsidiary of the Company or other entity under common control with the Company.

 

 

 

 

    	 	6	 

     

    

 

(b)       Non-Solicitation of Company Personnel. During the Term and during the Restriction Period, the Executive hereby agrees
that the Executive will not, either directly or through others, hire or attempt to hire any employee, consultant or independent
contractor of the Company or its Affiliates, other than an Officer or Director of the Company, or solicit or attempt to solicit
any such person to change or terminate her relationship with the Company or an Affiliate or otherwise to become an employee, consultant
or independent contractor to, for or of any other person or business entity, unless more than two (2) months shall have elapsed
between the last day of such person’s employment or service with the Company or Affiliate and the first date of such solicitation
or hiring or attempt to solicit or hire. The provisions of this subsection (b) shall not apply to general employment advertisements,
job fairs and other general public solicitations seeking to hire personnel.

 

(c)       Non-Solicitation of Customers. During the Term and during the Restriction Period, the Executive hereby agrees that
the Executive will not, either directly or through others, solicit, divert or appropriate, or attempt to solicit, divert or appropriate
any customer or prospective customer for which the Company has prepared written proposals for the purpose of providing such customer
or prospective customer with services or products directly competitive with those offered by the Company or an Affiliate during
the Term.

 

(d)       Proprietary Information. Executive acknowledges that Executive will have access to certain proprietary and confidential
information of the Company and its customers and vendors (collectively “Proprietary Information”). At all times, during
the Term of this Agreement, the Executive will hold in strictest confidence and will not disclose, use, lecture upon or publish
any of the Proprietary Information (defined below) of the Company or an Affiliate, except as such disclosure, use or publication
may be required in connection with the Executive’s work for the Company in accordance with this Agreement or as described
in Section 14© below, or unless the Company expressly authorizes such disclosure in writing. “Proprietary Information”
shall mean any and all confidential and/or proprietary knowledge, data or information of the Company and its Affiliates and shareholders,
including but not limited to written information relating to financial matters, investments, budgets, business plans, sales projections,
cost, pricing and pricing models, marketing and advertising plans, creative campaigns and themes, personnel matters, business
contacts, products and contemplated new products and services, processes, know-how, designs, methods, improvements, discoveries,
inventions, ideas, data, programs, and other works of authorship that are in writing and marked “Confidential”.

 

(e)       Reports to Government Entities. Nothing in this Agreement shall prohibit or restrict the Executive from initiating
communications directly with, responding to any inquiries from, providing testimony before, providing confidential information
to, reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly
with a self-regulatory authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission,
the Federal Drug Administration, the Department of Labor, the National Labor Relations Board, the Department of Justice, the Securities
and Exchange Commission, the United States Congress, and any agency Inspector General (collectively, the “Regulators”),
or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation.
The Executive does not need the prior authorization of the Company to engage in such communications, respond to such inquiries,
provide confidential information or documents to the Regulators, or make any such reports or disclosures to the Regulators. The
Executive is not required to notify the Company that the Executive has engaged in such communications with the Regulators. If
the Executive is required by law to disclose Proprietary Information, other than to Regulators as described above, the Executive
shall give prompt written notice to the Company so as to permit the Company to protect its interests in confidentiality to the
extent possible.

 

(f)       Invention Assignment. The Executive agrees that all inventions, innovations, improvements, developments, methods,
designs, analyses, reports, and all similar or related information which relates to the Company’s or its Affiliates’
actual or anticipated business, research and development or existing or future products or services and which are conceived, developed,
created, or made by Executive, alone or with others, whether or not patentable, registerable, or copyrightable, while employed
by the Company (“Work Product”) belong to the Company. The Executive will promptly disclose such Work Product
to the Board and perform all actions reasonably requested by the Board (whether during or after the Term) to establish and confirm
such ownership (including, without limitation, assignments, consents, powers of attorneys, applications for and procuring patents,
trademarks, service marks, or copyrights, and other instruments as the Company, in its sole discretion, may request). Executive
agrees to give the Company all assistance it may reasonably require, including the giving of testimony in any suit, action, investigation,
or other proceeding, to obtain, maintain, and protect the Company’s rights in the Work Product. Executive agrees as a condition
of employment to sign and be bound by the Company’s standard Inventions Assignment Agreement. The parties agree that the
inventions listed in Exhibit A to this Agreement, which is incorporated in and made a substantive part of this Agreement, are
excluded from the application of this subsection (f).

 

 

 

    	 	7	 

     

    

 

(g)       Return of Company Property. All records, files, lists, including computer generated lists, drawings, documents,
equipment, and similar items relating to the Company’s business that Executive shall prepare or receive from the Company
shall remain the Company’s sole and exclusive property. Upon termination of the Executive’s employment with
the Company for any reason, voluntarily or involuntarily, and at any earlier time the Company requests, the Executive will deliver
to the person designated by the Company all originals and copies of all documents and property of the Company or an Affiliate
that is in the Executive’s possession, under the Executive’s control or to which the Executive may have access. The
Executive shall keep one copy of all items related to the Company’s business listed above in this paragraph.

 

(h)       The foregoing provisions of subsections (a), (b), (c), and (d) shall not apply to the company or companies listed in Exhibit
B, as may amended from time-to-time by signed written agreement of the Board and Executive, which exhibit is incorporated in and
made a substantive part of this Agreement.

 

(i)        Notwithstanding anything in this Agreement to the contrary, and in addition to any other lawful rights and remedies available
to the Company, if the Executive breaches any of the Executive’s obligations under Section 14, the Company shall be obligated
to provide only the compensation and accrued benefits required by any Company benefit plans, policies or practices then applicable
to the Executive in accordance with the terms thereof. In such event, the Company may require that the Executive repay all amounts
theretofore paid to him pursuant to Section 6 hereof; and in such case, the Executive shall promptly repay such amounts on the
terms determined by the Company up to a maximum of fifty thousand dollars ($50,000.00).

 

(j)       The provisions of this Section 14 and Section 15 below shall survive any termination of the Executive’s employment
or the termination or expiration of this Agreement for a period of six months.

 

15.       Legal
and Equitable Remedies.

 

(a)       Because
the Executive’s services are personal and unique and the Executive has had and will continue to have access to and has become
and will continue to become acquainted with the proprietary information of the Company and its Affiliates, and because any breach
by the Executive of any of the restrictive covenants contained in Section 14 would result in irreparable injury and damage for
which money damages would not provide an adequate remedy, the Executive agrees that Company shall have the right to enforce Section
14 and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice
to any other rights and remedies that the Company may have for a breach, or threatened breach, of the restrictive covenants set
forth in Section 14. The Executive expressly consents to enforcement of Section 14 by means of temporary or permanent injunction
and other appropriate equitable relief in any competent court or arbitration tribunal, and agrees that in any action in which
the Company seeks injunction, specific performance or other equitable relief, the Executive will not assert or contend that any
of the provisions of Section 14 are unreasonable or otherwise unenforceable.

 

(b)       Any and all disputes arising under or relating to the interpretation or application of this Agreement or concerning Executive’s
employment with the Company or termination of employment shall be subject to final and binding arbitration in the Chicago, Illinois
under the then existing rules of the American Arbitration Association relating to employment matters. Judgment upon the award
rendered may be entered in any court of competent jurisdiction. The cost of arbitration and Executive’s legal expenses shall
be borne by the Company. Nothing contained in this subsection (b) shall limit the right of the Company to enforce by court injunction
or other equitable relief the Executive’s obligations under Section 14. In any court proceeding arising out of this Agreement,
the parties (1) irrevocably consent to the exclusive jurisdiction of the United States District Court for Northern District of
Illinois or if such court does not have jurisdiction or will not accept jurisdiction, to any court of general jurisdiction in
Illinois and (2) waive any objection to the laying of venue of any such proceeding in any such court.

 

 

 

 

    	 	8	 

     

    

 

(c)       Indemnification. In addition to any rights Executive may have under the Company’s charter or by-laws, the
Company agrees to indemnify Executive and hold Executive harmless, both during the Term and after the Term or Termination for
any reason, of this Agreement, against all costs, expenses (including, without limitation, fines, taxes and attorneys’ and
accountants’ fees) and liabilities (collectively, “Losses”) reasonably incurred by Executive in connection with
any claim, action, proceeding or investigation brought against or involving Executive with respect to, arising out of or in any
way relating to Executive’s employment with the Company or Executive’s service as a director of the Company. Executive
shall promptly notify the Company of any claim, action, proceeding or investigation under this paragraph and the Company shall
be entitled to participate in the defense of any such claim, action, proceeding or investigation and, if it so chooses, to assume
the defense with counsel selected by the Company; provided that Executive shall have the right to employ counsel to represent
him (at the Company’s expense) if Company counsel would have a “conflict of interest” in representing both the
Company and Executive. The Company shall not settle or compromise any claim, action, proceeding or investigation without Executive’s
consent, which consent shall not be unreasonably withheld; provided, however, that such consent shall not be required if the settlement
entails only the payment of money and the Company fully indemnifies Executive in connection therewith. The Company further agrees
to advance any and all expenses (including, without limitation, the fees and expenses of counsel) reasonably incurred by the Executive
in connection with any such claim, action, proceeding or investigation. The Company, as soon as reasonably possible, will maintains
a policy of directors’ and officers’ liability insurance covering Executive and, notwithstanding the expiration or
earlier termination of this Agreement, the Company shall maintain a directors’ and officers’ liability insurance policy
covering Executive for a period of time following such expiration or earlier termination equal to the statute of limitations for
any claim that may be asserted against Executive for which coverage is available under such directors’ and officers’
liability insurance policy. All provisions of this paragraph shall survive the termination of this Agreement for any reason.

 

16.       Survival.
The respective rights and obligations of the parties under this Agreement, including, but not limited to, Sections 14 and
15, shall survive any termination of the Executive’s employment or termination or expiration of this Agreement to the extent
necessary to the intended preservation of such rights and obligations.

 

17.       No
Mitigation or Set Off. In no event shall the Executive be obligated to seek other employment or take any other action by way
of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement and such amounts shall not
be reduced, regardless of whether the Executive obtains other employment. During the pendency of any claim between the Company
and Executive, the Company’s obligation to make the payments provided for in this Agreement and otherwise to perform its
obligations hereunder with respect to any set-off, counterclaim, recoupment, defense or other right which the Company may have
against the Executive or others, may be determined on an interlocutory basis by a competent court or arbitration tribunal.

 

18.       Notices.
All notices and other communications required or permitted under this Agreement or necessary or convenient in connection herewith
shall be in writing and shall be deemed to have been given when hand delivered or mailed by registered or certified mail, as follows
(provided that notice of change of address shall be deemed given only when received):

 

If
to the Company, to:

 

Odyssey
Group International

Irvine
CA

Attention:
Chair of the Board of Directors

 

If
to the Executive, to the most recent address on file with the Company or to such other names or addresses as the Company or the
Executive, as the case may be, shall designate by notice to each other person entitled to receive notices in the manner specified
in this Section.

 

 

 

 

    	 	9	 

     

    

 

19.       Withholding.
All payments under this Agreement shall be made subject to applicable tax withholding, and the Company shall withhold from
any payments under this Agreement all federal, state and local taxes as the Company is required to withhold pursuant to any law
or governmental rule or regulation.

 

20.       Remedies
Cumulative; No Waiver. No remedy conferred upon a party by this Agreement is intended to be exclusive of any other remedy,
and each and every such remedy shall be cumulative and shall be in addition to any other remedy given under this Agreement or
now or hereafter existing at law or in equity. No delay or omission by a party in exercising any right, remedy or power under
this Agreement or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may
be exercised by such party from time-to-time and as often as may be deemed expedient or necessary by such party in its sole discretion.

 

21.       Assignment.
All of the terms and provisions of this Agreement shall be binding upon and inure to the benefit of and be enforceable by
the respective heirs, executors, administrators, legal representatives, successors and assigns of the parties hereto, except that
the duties and responsibilities of the Executive under this Agreement are of a personal nature and shall not be assignable or
delegable in whole or in part by the Executive. Successors of the Company shall include, without limitation, any company or companies
acquiring, directly or indirectly, all or substantially all of the assets of the Company, whether by merger, consolidation, purchase,
lease, or otherwise, and such successor shall thereafter be deemed “the Company” for the purpose of this Section 21.

 

22.       Entire
Agreement.

 

(a)       This Agreement, including all referenced addendums and exhibits, embodies the entire agreement of the parties with respect
to its subject matter and merges with and supersedes all prior discussions, agreements, commitments, or understandings of every
kind and nature relating to Executive’s employment, whether oral or written, between Executive and the Company. Neither
party shall be bound by any term or condition other than as is expressly set forth in this Agreement.

 

(b)       Executive represents and agrees that she fully understands her right to discuss all aspects of this Agreement with her
private attorney, that to the extent she desired Executive availed himself of this right, that Executive has carefully read and
fully understands all of the provisions of the Agreement, that Executive is competent to execute this Agreement, that her decision
to execute this Agreement has not been obtained by any duress, that Executive freely and voluntarily enters into this Agreement,
and that Executive has read this document in its entirety and fully understands the meaning, intent, and consequences of this
Agreement.

 

23.       Amendment.
This Agreement may be changed, modified or amended only by a written document signed by the Executive and the Board.

 

24.       Severability.
If any provision of this Agreement or application thereof to anyone or under any circumstances is adjudicated to be invalid
or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect any other provision or application
of this Agreement which can be given effect without the invalid or unenforceable provision or application and shall not invalidate
or render unenforceable such provision or application in any other jurisdiction. If any provision is held void, invalid or unenforceable
with respect to particular circumstances, it shall nevertheless remain in full force and effect in all other circumstances.

 

25.       Governing
Law. This Agreement and any claims arising out of relating to this Agreement, whether in contract or tort, statutory or common
law, shall be governed exclusively by, and construed in accordance with the laws of the State of Nevada without regard to principles
of conflicts of laws.

 

 

 

 

    	 	10	 

     

    

 

26.       Forum
Selection and Consent to Jurisdiction. ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT,
SHALL BE BROUGHT AND MAINTAINED EXCLUSIVELY IN THE COURTS OF THE STATE OF NEVADA OR IN THE UNITED STATES DISTRICT COURT FOR THE
DISTRICT OF NEVADA; THE PARTIES HEREBY EXPRESSLY AND IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION
WHICH THEY MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE
AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.

 

27.       Waiver
of Jury Trial. EACH PARTY HEREBY WAIVES ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY
RIGHTS UNDER THIS AGREEMENT AND ANY AMENDMENT, INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED OR WHICH MAY IN THE FUTURE BE DELIVERED
IN CONNECTION HEREWITH OR THEREWITH OR ARISING FROM ANY RELATIONSHIP EXISTING IN CONNECTION WITH ANY OF THE FOREGOING, AND AGREES
THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY.

 

28.       Service
of Process: Each party hereto hereby consents to service of process in any action between any of the Parties hereto arising
in whole or in part under or in connection with this Agreement, any document related to, or the negotiation, terms or performance
hereof or thereof, (a) in any manner permitted by Nevada law or (b) by overnight delivery by a nationally recognized courier service
at the respective address specified in this Agreement, and waives and agrees not to assert (by way of motion, as a defense or
otherwise) in any such Action any claim that service of process made in accordance with clause (a) or (b) does not constitute
good and valid service of process.

 

29.       Counterparts;
Electronic Transmission. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all
of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail
or other means of electronic transmission (including an electronically-signed PDF) shall be deemed to have the same legal effect
as delivery of an original signed copy of this Agreement.

 

Read
and Agreed to:

 

	By: /s/Christine Farrell  	Date: January 21, 2021

Christine
Farrell

 

 

 

Odyssey
Group International, Inc.

 

	By: /s/ Joseph M. Redmond 	Date: January 21, 2021

Joseph
M. Redmond

 

 

 

 

 

 

 

    	 	11	 

     

    

 

EXHIBIT A

 

Inventions
Assignment Agreement

 

 

 

EXHIBIT B

 

Companies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	12Exhibit 4.4

 

WARRANT AGREEMENT

 

THIS WARRANT AGREEMENT
(this “Agreement”), dated as of [_______], 2021, is by and between Growth Capital Acquisition Corp.,
a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York
corporation, as warrant agent (the “Warrant Agent”, also referred to herein as the
 “Transfer Agent”).

 

WHEREAS, the Company
is engaged in an initial public offering (the “Offering”) of units of the Company’s equity securities,
each such unit comprised of one share of Class A common stock of the Company, par value $0.0001 per share (“Common
Stock”) and one-half of one redeemable Public Warrant (as defined below) (the “Units”)
and, in connection therewith, has determined to issue and deliver up to 6,250,000 warrants (or up to 7,187,500 warrants if the
Over-allotment Option is exercised in full) to public investors in the Offering (the “Public Warrants”);
and

 

WHEREAS, on [_______],
2021, the Company entered into that certain Private Placement Warrants Subscription Agreement with Growth Capital Sponsor LLC,
a New York limited liability company (the “Sponsor”), Nautilus Carriers LLC and HB Strategies LLC, each
a Delaware limited liability company (collectively, the “Subscribers”) pursuant to which the Subscribers
agreed to purchase an aggregate of 4,180,000 warrants (“Private Placement Warrants) simultaneously with the
closing of the Offering (or up to 4,600,000 Private Placement Warrants if the Over-allotment Option is exercised in full) in connection
therewith bearing the legend set forth in Exhibit B hereto; and

 

WHEREAS, in order to
finance the Company’s transaction costs in connection with an intended initial Business Combination (as defined below), the
Sponsor or an affiliate of the Sponsor or certain of the Company’s executive officers and directors may, but are not obligated
to, loan to the Company funds as the Company may require, of which up to $1,500,000 of such loans may be convertible into up to
an additional 150,000 Units at a price of $1.00 per warrant, and in connection therewith (the “Working Capital Warrants”);
and

 

WHEREAS, following
consummation of the Offering, the Company may issue additional warrants (“Post IPO Warrants”; together
with the Private Placement Warrants, the Working Capital Warrants and the Public Warrants, the “Warrants”)
in connection with, or following the consummation by the Company of, a Business Combination (defined below); and

 

WHEREAS, the Company
has filed with the Securities and Exchange Commission (the “Commission”) a registration statement on
Form S-1, File No. 333-248087 (the “Registration Statement”) and prospectus (the “Prospectus”),
for the registration, under the Securities Act of 1933, as amended (the “Securities Act”), of the Units,
the Public Warrants and the Common Stock included in the Units; and

 

WHEREAS, the Company
desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance,
registration, transfer, exchange, redemption and exercise of the Warrants; and

 

WHEREAS, the Company
desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the
respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and

 

WHEREAS, all acts and
things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned
by or on behalf of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company, and to authorize
the execution and delivery of this Agreement.

 

     

     

    

 

NOW, THEREFORE, in
consideration of the mutual agreements herein contained, the parties hereto agree as follows:

 

1. Appointment
of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants, and the Warrant
Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this
Agreement.

 

2. Warrants.

 

2.1 Form
of Warrant. Each Warrant shall be issued in registered form only, and, if a physical certificate is issued, shall be in
substantially the form of Exhibit A hereto, the provisions of which are incorporated herein and shall be signed
by, or bear the facsimile signature of, the Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer,
Secretary or other principal officer of the Company. In the event the person whose facsimile signature has been placed upon any
Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may
be issued with the same effect as if he or she had not ceased to be such at the date of issuance.

 

2.2 Effect
of Countersignature. If a physical certificate is issued, unless and until countersigned by the Warrant Agent pursuant to this
Agreement, a Warrant certificate shall be invalid and of no effect and may not be exercised by the holder thereof.

 

2.3 Registration.

 

2.3.1 Warrant
Register. The Warrant Agent shall maintain books (the “Warrant Register”) for the registration
of original issuance and the registration of transfer of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent
shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance
with instructions delivered to the Warrant Agent by the Company. All of the Public Warrants shall initially be represented by one
or more book-entry certificates (each, a “Book-Entry Warrant Certificate”) deposited with The Depository
Trust Company (the “Depositary”) and registered in the name of Cede & Co., a nominee of the Depositary.
Ownership of beneficial interests in the Public Warrants shall be shown on, and the transfer of such ownership shall be effected
through, records maintained by (i) the Depositary or its nominee for each Book-Entry Warrant Certificate, or (ii) institutions
that have accounts with the Depositary (each such institution, with respect to a Warrant in its account, a “Participant”).

 

If the Depositary
subsequently ceases to make its book-entry settlement system available for the Public Warrants, the Company may instruct the Warrant
Agent regarding making other arrangements for book-entry settlement. In the event that the Public Warrants are not eligible for,
or it is no longer necessary to have the Public Warrants available in, book-entry form, the Warrant Agent shall provide written
instructions to the Depositary to deliver to the Warrant Agent for cancellation each Book-Entry Warrant Certificate, and the Company
shall instruct the Warrant Agent to deliver to the Depositary definitive certificates in physical form evidencing such Warrants
(“Definitive Warrant Certificate”). Such Definitive Warrant Certificate shall be in the form annexed
hereto as Exhibit A, with appropriate insertions, modifications and omissions, as provided above.

 

2.3.2 Registered
Holder. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and
treat the person in whose name such Warrant is registered in the Warrant Register (the “Registered Holder”)
as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other
writing on a Definitive Warrant Certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any
exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to
the contrary.

  

2.4 Detachability
of Warrants. The Common Stock and Public Warrants comprising the Units shall begin separate trading on the 52nd day following
the date of the Prospectus or, if such 52nd day is not on a day, other than a Saturday, Sunday or federal holiday, on which banks
in New York City are generally open for normal business (a “Business Day”), then on the immediately succeeding
Business Day following such date, or earlier (the “Detachment Date”) with the consent of Maxim Group
LLC (“Maxim”), as representative of the several underwriters, but in no event shall the Common Stock
and the Public Warrants comprising the Units be separately traded until (A) the Company has filed a current report on Form 8-K
with the Commission containing an audited balance sheet reflecting the receipt by the Company of the gross proceeds of the Offering,
including the proceeds received by the Company from the exercise by the underwriters of their right to purchase additional Units
in the Offering (the “Over-Allotment Option”), if the Over-Allotment Option is exercised prior to the
filing of the Form 8-K, and (B) the Company issues a press release and files with the Commission a current report on Form 8-K announcing
when such separate trading shall begin.

 

     

     

    

 

2.5 No Fractional
Warrants Other Than as Part of Units. The Company shall not issue fractional Warrants other than as part of the Units, each
of which is comprised of one share of Common Stock and one-half of one Public Warrant. If, upon the detachment of Public Warrants
from Units or otherwise, a holder of Warrants would be entitled to receive a fractional Warrant, the Company shall round down to
the nearest whole number the number of Warrants to be issued to such holder.

 

2.6 Private
Placement Warrants and Working Capital Warrants. The Private Placement Warrants and the Working Capital Warrants shall be identical
to the Public Warrants, except that so long as they are held by the Subscribers, or any Permitted Transferees (as defined below),
as applicable, the Private Placement Warrants and the Working Capital Warrants: (i) may be exercised for cash or on a cashless
basis, pursuant to subsection 3.3.1(c) hereof, (ii) may not be transferred, assigned or sold until thirty (30)
days after the completion by the Company of an initial Business Combination (as defined below), and (iii) shall not be redeemable
by the Company; provided, however, that in the case of (ii) the Private Placement Warrants and the Working
Capital Warrants and any shares of Common Stock held by the Subscribers or any Permitted Transferees, as applicable, and issued
upon exercise of the Private Placement Warrants and the Working Capital Warrants may be transferred by the holders thereof:

 

(a) to the Company’s
officers or directors, any affiliate or family member of any of the Company’s officers or directors, any members of our sponsor
or other initial stockholders, or any current or future affiliates of our sponsor or other initial stockholders;

 

(b) in the case of
an individual, by gift to a member such individual’s immediate family or to a trust, the beneficiary of which is a member
of such individual’s immediate family, an affiliate of such individual or to a charitable organization;

 

(c) in the case of
an individual, by virtue of the laws of descent and distribution upon death of such person;

 

(d) in the case of
an individual, pursuant to a qualified domestic relations order;

 

(e) by private sales
or transfers made in connection with the consummation of an initial Business Combination at prices no greater than the price at
which the Warrants were originally purchased;

 

(f) in the event
of the Company’s liquidation prior to consummation of the Company’s Business Combination; or

 

(g) by virtue of
the laws of the State of Delaware or the Sponsor’s limited liability company agreement of our initial stockholders upon dissolution
of the Sponsor;

 

provided, however, that,
in the case of clauses (a) through (e) or (g), these transferees (the “Permitted Transferees”)
enter into a written agreement with the Company agreeing to be bound by the transfer restrictions in this Agreement.

   

2.7 Working
Capital Warrants. The Working Capital Warrants shall be identical to the Private Placement Warrants.

 

2.8 Post-IPO
Warrants. The Post-IPO Warrants, when and if issued, shall have the same terms and be in the same form as the Public Warrants
except as may be agreed upon by the Company.

 

3. Terms and
Exercise of Warrants.

 

3.1 Warrant
Price. Each whole Warrant shall entitle the Registered Holder thereof, subject to the provisions of such Warrant and of
this Agreement, to purchase from the Company the number of shares of Common Stock stated therein, at the price of $11.50 per
share, subject to the adjustments provided in Section 4 hereof and in the last sentence of
this Section 3.1. The term “Warrant Price” as used in this Agreement shall mean the price per share
at which shares of Common Stock may be purchased at the time a Warrant is exercised. The Company in its sole discretion may
lower the Warrant Price at any time prior to the Expiration Date (as defined below) for a period of not less than twenty (20)
Business Days, provided, that the Company shall provide at least twenty (20) days prior written notice of such reduction to
Registered Holders of the Warrants and, provided further that any such reduction shall be identical among all of the
Warrants.

 

     

     

    

 

3.2 Duration
of Warrants. A Warrant may be exercised only during the period (the “Exercise Period”)
commencing on the later of: (i) the date that is thirty (30) days after the first date on which the Company completes a
merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, involving
the Company and one or more businesses (a “Business Combination”), or (ii) the date that is twelve
(12) months from the date of the closing of the Offering, and terminating at 5:00 p.m., New York City time on the earlier to
occur of: (x) the date that is five (5) years after the date on which the Company completes its initial Business Combination,
(y) the liquidation of the Company, or (z) other than with respect to the Private Placement Warrants and the Working Capital
Warrants to the extent then held by the original purchasers thereof or their Permitted Transferees, the Redemption Date (as
defined below) as provided in Section 6.2 hereof (the “Expiration
Date”); provided, however, that the exercise of any Warrant shall be subject to the
satisfaction of any applicable conditions, as set forth in subsection 3.3.2 below with respect to an
effective registration statement. Except with respect to the right to receive the Redemption Price (as defined below) (other
than with respect to a Private Placement Warrant or a Working Capital Warrant to the extent then held by the original
purchasers thereof or their Permitted Transferees in the event of a redemption as set forth in Section
6 hereof), each outstanding Warrant (other than a Private Placement Warrant or a Working Capital Warrant to the
extent then held by the original purchasers thereof or their Permitted Transferees in the event of a redemption) not
exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof
under this Agreement shall cease at 5:00 p.m. New York City time on the Expiration Date. The Company in its sole discretion
may extend the duration of the Warrants by delaying the Expiration Date; provided, that the Company shall provide
at least twenty (20) days prior written notice of any such extension to Registered Holders of the Warrants and, provided
further that any such extension shall be identical in duration among all the Warrants.

 

3.3 Exercise
of Warrants.

 

3.3.1 Payment.
Subject to the provisions of the Warrant and this Agreement, a Warrant may be exercised by the Registered Holder thereof by delivering
to the Warrant Agent at its corporate trust department (i) the Definitive Warrant Certificate evidencing the Warrants to be exercised,
or, in the case of a Book-Entry Warrant Certificate, the Warrants to be exercised (the “Book-Entry Warrants”)
on the records of the Depositary to an account of the Warrant Agent at the Depositary designated for such purposes in writing by
the Warrant Agent to the Depositary from time to time, (ii) an election to purchase (“Election to Purchase”)
shares of Common Stock pursuant to the exercise of a Warrant, properly completed and executed by the Registered Holder on the reverse
of the Definitive Warrant Certificate or, in the case of a Book-Entry Warrant Certificate, properly delivered by the Participant
in accordance with the Depositary’s procedures, and (iii) payment in full of the Warrant Price for each full share of Common
Stock as to which the Warrant is exercised and any and all applicable taxes due in connection with the exercise of the Warrant,
the exchange of the Warrant for the shares of Common Stock and the issuance of such shares of Common Stock, as follows:

 

(a) by certified
check payable to the order of the Warrant Agent or by wire transfer;

 

(b) in the event
of a redemption pursuant to Section 6 hereof in which the Company’s board of directors (the “Board”)
has elected to require all holders of the Warrants to exercise such Warrants on a “cashless basis,” by surrendering
the Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number
of shares of Common Stock underlying the Warrants, multiplied by the difference between the Warrant Price and the “Fair Market
Value”, as defined in this subsection 3.3.1(b) by (y) the Fair Market Value. Solely for purposes of this subsection
3.3.1(b) and Section 6.3, the “Fair Market Value” shall mean the average last sale price of the
Common Stock for the ten (10) trading days ending on the third trading day prior to the date on which the notice of redemption
is sent to the holders of the Warrants, pursuant to Section 6 hereof;

 

(c) with
respect to any Private Placement Warrant or Working Capital Warrant, so long as such Private Placement Warrant or Working
Capital Warrant is held by a Subscriber or a Permitted Transferee, as applicable, by surrendering the Warrants for that
number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common
Stock underlying the Warrants, multiplied by the difference between the Warrant Price and the “Fair Market
Value”, as defined in this subsection 3.3.1(c), by (y) the Fair Market Value. Solely for purposes of
this subsection 3.3.1(c), the “Fair Market Value” shall mean the average reported last sale price of
the Common Stock for the ten (10) trading days ending on the third trading day prior to the date on which notice of exercise
of the Warrant is sent to the Warrant Agent; or

 

     

     

    

 

(d) as provided in Section
7.4 hereof.

 

3.3.2 Issuance
of Shares of Common Stock on Exercise. As soon as practicable after the exercise of any Warrant and the clearance of the funds
in payment of the Warrant Price (if payment is pursuant to subsection 3.3.1(a)), the Company shall issue to the Registered
Holder of such Warrant a book-entry position or certificate, as applicable, for the number of full shares of Common Stock to which
he, she or it is entitled, registered in such name or names as may be directed by him, her or it, and if such Warrant shall not
have been exercised in full, a new book-entry position or countersigned Warrant, as applicable, for the number of shares of Common
Stock as to which such Warrant shall not have been exercised. If fewer than all the Warrants evidenced by a Book-Entry Warrant
Certificate are exercised, a notation shall be made to the records maintained by the Depositary, its nominee for each Book-Entry
Warrant Certificate, or a Participant, as appropriate, evidencing the balance of the Warrants remaining after such exercise. Notwithstanding
the foregoing, the Company shall not be obligated to deliver any shares of Common Stock pursuant to the exercise of a Warrant and
shall have no obligation to settle such Warrant exercise unless a registration statement under the Securities Act with respect
to the shares of Common Stock underlying the Public Warrants is then effective and a prospectus relating thereto is current, subject
to the Company’s satisfying its obligations under Section 7.4. No Warrant shall be exercisable and the Company
shall not be obligated to issue shares of Common Stock upon exercise of a Warrant unless the Common Stock issuable upon such Warrant
exercise has been registered, qualified or deemed to be exempt from registration or qualification under the securities laws of
the state of residence of the Registered Holder of the Warrants, except pursuant to Section 7.4. In the event that
the conditions in the two immediately preceding sentences are not satisfied with respect to a Warrant, the holder of such Warrant
shall not be entitled to exercise such Warrant and such Warrant may have no value and expire worthless, in which case the purchaser
of a Unit containing such Public Warrants shall have paid the full purchase price for the Unit solely for the shares of Common
Stock underlying such Unit. In no event will the Company be required to net cash settle the Warrant exercise. The Company may require
holders of Public Warrants to settle the Warrant on a “cashless basis” pursuant to subsection 3.3.1(b) and Section
7.4. If, by reason of any exercise of Warrants on a “cashless basis”, the holder of any Warrant would be entitled,
upon the exercise of such Warrant, to receive a fractional interest in a share of Common Stock, the Company shall round down to
the nearest whole number, the number of shares of Common Stock to be issued to such holder. Notwithstanding anything herein to
the contrary, for as long as any of the Private Warrants are held by a Subscriber or its designees or affiliates, such Warrants
may not be exercised after five years from the effective date of the Registration Statement.

 

3.3.3 Valid
Issuance. All shares of Common Stock issued upon the proper exercise of a Warrant in conformity with this Agreement shall be
validly issued, fully paid and non-assessable.

 

3.3.4 Date
of Issuance. Each person in whose name any book-entry position or certificate, as applicable, for shares of Common Stock is
issued shall for all purposes be deemed to have become the holder of record of such shares of Common Stock on the date on which
the Warrant, or book-entry position representing such Warrant, was surrendered and payment of the Warrant Price was made, irrespective
of the date of delivery of such certificate in the case of a certificated Warrant, except that, if the date of such surrender and
payment is a date when the share transfer books of the Company or book-entry system of the Warrant Agent are closed, such person
shall be deemed to have become the holder of such shares of Common Stock at the close of business on the next succeeding date on
which the share transfer books or book-entry system are open.

 

3.3.5 Maximum
Percentage. A holder of a Warrant may notify the Company in writing in the event it elects to be subject to the
provisions contained in this subsection 3.3.5; however, no holder of a Warrant shall be subject to
this subsection 3.3.5 unless he, she or it makes such election. If the election is made by a holder, the
Warrant Agent shall not effect the exercise of the holder’s Warrant, and such holder shall not have the right to
exercise such Warrant, to the extent that after giving effect to such exercise, such person (together with such
person’s affiliates), to the Warrant Agent’s actual knowledge, would beneficially own in excess of 4.9% or 9.8%
(or such other amount as a holder may specify)(the “Maximum Percentage”) of the shares of Common
Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate
number of shares of Common Stock beneficially owned by such person and its affiliates shall include the number of shares of
Common Stock issuable upon exercise of the Warrant with respect to which the determination of such sentence is being made,
but shall exclude shares of Common Stock that would be issuable upon (x) exercise of the remaining, unexercised portion of
the Warrant beneficially owned by such person and its affiliates and (y) exercise or conversion of the unexercised or
unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates (including,
without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion
or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this
paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”). For purposes of the Warrant, in determining the number of
outstanding shares of Common Stock, the holder may rely on the number of outstanding shares of Common Stock as reflected in
(1) the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, current report on Form 8-K or
other public filing with the Commission as the case may be, (2) a more recent public announcement by the Company or (3) any
other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. For any
reason at any time, upon the written request of the holder of the Warrant, the Company shall, within two (2) Business Days,
confirm orally and in writing to such holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of equity
securities of the Company by the holder and its affiliates since the date as of which such number of outstanding shares of
Common Stock was reported. By written notice to the Company, the holder of a Warrant may from time to time increase or
decrease the Maximum Percentage applicable to such holder to any other percentage specified in such
notice; provided, however, that any such increase shall not be effective until the sixty-first (61st)
day after such notice is delivered to the Company.

 

     

     

    

  

4. Adjustments.

 

4.1 Stock
Dividends.

 

4.1.1 Split-Ups.
If after the date hereof, and subject to the provisions of Section 4.6 below, the number of outstanding shares
of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a split-up of shares of Common Stock
or other similar event, then, on the effective date of such stock dividend, split-up or similar event, the number of shares of
Common Stock issuable on exercise of each Warrant shall be increased in proportion to such increase in the outstanding shares of
Common Stock. A rights offering to holders of the Common Stock entitling holders to purchase shares of Common Stock at a price
less than the “Fair Market Value” (as defined below) shall be deemed a stock dividend of a number of shares of Common
Stock equal to the product of (i) the number of shares of Common Stock actually sold in such rights offering (or issuable under
any other equity securities sold in such rights offering that are convertible into or exercisable for the Common Stock) and (ii)
one (1) minus the quotient of (x) the price per share of Common Stock paid in such rights offering divided by (y) the Fair Market
Value. For purposes of this subsection 4.1.1, (i) if the rights offering is for securities convertible into or exercisable
for Common Stock, in determining the price payable for Common Stock, there shall be taken into account any consideration received
for such rights, as well as any additional amount payable upon exercise or conversion and (ii) “Fair Market Value”
means the volume weighted average price of the Common Stock as reported during the ten (10) trading day period ending on the trading
day prior to the first date on which the shares of Common Stock trade on the applicable exchange or in the applicable market, regular
way, without the right to receive such rights.

  

4.1.2 Extraordinary
Dividends. If the Company, at any time while the Warrants are outstanding and unexpired, shall pay a dividend or make a
distribution in cash, securities or other assets to the holders of the Common Stock on account of such shares of Common Stock
(or other shares of the Company’s capital stock into which the Warrants are convertible), other than (a) as described
in subsection 4.1.1 above, (b) Ordinary Cash Dividends (as defined below), (c) to satisfy the redemption
rights of the holders of the Common Stock in connection with a proposed initial Business Combination, (d) as a result of the
repurchase of shares of Common Stock by the Company if a proposed Business Combination is presented to the stockholders of
the Company for approval, (e) to satisfy the redemption rights of the holders of Common Stock in connection with a
stockholder vote to amend the Company’s amended and restated certificate of incorporation to modify the substance or
timing of the Company’s obligation to redeem 100% of the public shares of Common Stock if the Company does not complete
the Business Combination within the period set forth in the Company’s amended and restated certificate of incorporation
or (f) in connection with the redemption of public shares of Common Stock upon the failure of the Company to complete its
initial Business Combination and any subsequent distribution of its assets upon its liquidation (any such non-excluded event
being referred to herein as an “Extraordinary Dividend”), then the Warrant Price shall be
decreased, effective immediately after the effective date of such Extraordinary Dividend, by the amount of cash and/or the
fair market value (as determined by the Board, in good faith) of any securities or other assets paid on each share of Common
Stock in respect of such Extraordinary Dividend. For purposes of this subsection 4.1.2, “Ordinary
Cash Dividends” means any cash dividend or cash distribution which, when combined on a per share basis, with
the per share amounts of all other cash dividends and cash distributions paid on the Common Stock during the 365-day period
ending on the date of declaration of such dividend or distribution (as adjusted to appropriately reflect any of the events
referred to in other subsections of this Section 4 and excluding cash dividends or cash distributions that
resulted in an adjustment to the Warrant Price or to the number of shares of Common Stock issuable on exercise of each
Warrant) does not exceed $0.50 (being 5% of the offering price of the Units in the Offering).

 

     

     

    

 

4.2 Aggregation
of Shares. If after the date hereof, and subject to the provisions of Section 4.6 hereof, the number of outstanding
shares of Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Common
Stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification
or similar event, the number of shares of Common Stock issuable on exercise of each Warrant shall be decreased in proportion to
such decrease in outstanding shares of Common Stock.

 

4.3 Adjustments
in Exercise Price.

 

4.3.1 Whenever the
number of shares of Common Stock purchasable upon the exercise of the Warrants is adjusted, as provided in subsection 4.1.1 or Section
4.2 above, the Warrant Price shall be adjusted (to the nearest cent) by multiplying such Warrant Price immediately prior to
such adjustment by a fraction (x) the numerator of which shall be the number of shares of Common Stock purchasable upon the exercise
of the Warrants immediately prior to such adjustment, and (y) the denominator of which shall be the number of shares of Common
Stock so purchasable immediately thereafter.

 

4.3.2 If (i) the
Company issues additional shares of Common Stock or securities convertible into or exercisable or exchangeable for shares of Common
Stock for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective
issue price of less than $9.20 per share of Common Stock, with such issue price or effective issue price to be determined in good
faith by the Board (and in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder
shares held by such holder or affiliates, as applicable, prior to such issuance) (the “New Issuance Price”),
(ii) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon,
available for the funding of the initial Business Combination on the date of the consummation thereof (net of redemptions) and
(iii) the volume weighted average trading price of the Common Stock during the 20 trading day period starting on the trading day
prior to the day on which the Company consummates the initial Business Combination (such price, the “Market Value”)
is below $9.20 per share, the Warrant Price shall be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market
Value and the New Issuance Price and the Redemption Trigger Price (as defined below) shall be adjusted to equal to 180% of the
greater of the Market Value and the Newly Issued Price.

 

     

     

    

 

4.4 Replacement
of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding shares of
Common Stock (other than a change under subsections 4.1.1 or 4.1.2 or Section
4.2 hereof or that solely affects the par value of such shares of Common Stock), or in the case of any merger or
consolidation of the Company with or into another entity or conversion of the Company as another entity (other than a
consolidation or merger in which the Company is the continuing corporation and that does not result in any reclassification
or reorganization of the outstanding shares of Common Stock), or in the case of any sale or conveyance to another entity of
the assets or other property of the Company as an entirety or substantially as an entirety in connection with which the
Company is dissolved, the holders of the Warrants shall thereafter have the right to purchase and receive, upon the basis and
upon the terms and conditions specified in the Warrants and in lieu of the shares of Common Stock of the Company immediately
theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of
stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or
consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Warrants would have received
if such holder had exercised his, her or its Warrant(s) immediately prior to such event (the “Alternative
Issuance” ); provided, however, that in connection with the closing of any such consolidation,
merger, sale or conveyance, the successor or purchasing entity shall execute an amendment hereto with the Warrant Agent
providing for delivery of such Alternative Issuance; provided, further, that (i) if the holders of
the Common Stock were entitled to exercise a right of election as to the kind or amount of securities, cash or other assets
receivable upon such consolidation or merger, then the kind and amount of securities, cash or other assets constituting the
Alternative Issuance for which each Warrant shall become exercisable shall be deemed to be the weighted average of the kind
and amount received per share by the holders of the Common Stock in such consolidation or merger that affirmatively make such
election, and (ii) if a tender, exchange or redemption offer shall have been made to and accepted by the holders of the
Common Stock (other than a tender, exchange or redemption offer made by the Company in connection with redemption rights held
by stockholders of the Company as provided for in the Company’s amended and restated certificate of incorporation or as
a result of the repurchase of shares of Common Stock by the Company if a proposed initial Business Combination is presented
to the stockholders of the Company for approval) under circumstances in which, upon completion of such tender or exchange
offer, the maker thereof, together with members of any group (within the meaning of Rule 13d-5(b)(1) under the Exchange Act
(or any successor rule)) of which such maker is a part, and together with any affiliate or associate of such maker (within
the meaning of Rule 12b-2 under the Exchange Act (or any successor rule)) and any members of any such group of which any such
affiliate or associate is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act (or any successor
rule)) more than 50% of the outstanding shares of Common Stock, the holder of a Warrant shall be entitled to receive as the
Alternative Issuance, the highest amount of cash, securities or other property to which such holder would actually have been
entitled as a stockholder if such Warrant holder had exercised the Warrant prior to the expiration of such tender or exchange
offer, accepted such offer and all of the Common Stock held by such holder had been purchased pursuant to such tender or
exchange offer, subject to adjustments (from and after the consummation of such tender or exchange offer) as nearly
equivalent as possible to the adjustments provided for in this Section
4; provided, further, that if less than 70% of the consideration receivable by the holders of the
Common Stock in the applicable event is payable in the form of common stock in the successor entity that is listed for
trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for
trading or quoted immediately following such event, and if the Registered Holder properly exercises the Warrant within thirty
(30) days following the public disclosure of the consummation of such applicable event by the Company pursuant to a Current
Report on Form 8-K filed with the Commission, the Warrant Price shall be reduced by an amount (in dollars) (but in no event
less than zero) equal to the difference of (i) the Warrant Price in effect prior to such reduction minus (ii) (A) the Per
Share Consideration (as defined below) minus (B) the Black-Scholes Warrant Value (as defined below). The
 “Black-Scholes Warrant Value” means the value of a Warrant immediately prior to the consummation of
the applicable event based on the Black-Scholes Warrant Model for a Capped American Call on Bloomberg Financial Markets
(“Bloomberg”). For purposes of calculating such amount, (1) Section 6 of this
Agreement shall be taken into account, (2) the price of each share of Common Stock shall be the volume weighted average price
of the Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the effective date
of the applicable event, (3) the assumed volatility shall be the 90 day volatility obtained from the HVT function on
Bloomberg determined as of the trading day immediately prior to the day of the announcement of the applicable event, and (4)
the assumed risk-free interest rate shall correspond to the U.S. Treasury rate for a period equal to the remaining term of
the Warrant. “Per Share Consideration” means (i) if the consideration paid
to holders of the Common Stock consists exclusively of cash, the amount of such cash per share of Common Stock, and (ii) in
all other cases, the amount of cash per share of Common Stock, if any, plus the volume weighted average price of the Common
Stock as reported during the ten (10) trading day period ending on the trading day prior to the effective date of the
applicable event. If any reclassification or reorganization also results in a change in shares of Common Stock covered
by subsection 4.1.1, then such adjustment shall be made pursuant to subsection
4.1.1 or Sections 4.2, 4.3 and this Section 4.4. The provisions of
this Section 4.4 shall similarly apply to successive reclassifications, reorganizations, mergers or
consolidations, sales or other transfers. In no event will the Warrant Price be reduced to less than the par value per share
issuable upon exercise of the Warrant.

  

4.5 Notices
of Changes in Warrant. Upon every adjustment of the Warrant Price or the number of shares of Common Stock issuable upon exercise
of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting
from such adjustment and the increase or decrease, if any, in the number of shares of Common Stock purchasable at such price upon
the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation
is based. Upon the occurrence of any event specified in Sections 4.1, 4.2, 4.3 or 4.4,
the Company shall give written notice of the occurrence of such event to each holder of a Warrant, at the last address set forth
for such holder in the Warrant Register, of the record date or the effective date of the event. Failure to give such notice, or
any defect therein, shall not affect the legality or validity of such event.

 

     

     

    

 

4.6 No Fractional
Shares. Notwithstanding any provision contained in this Agreement to the contrary, the Company shall not issue fractional shares
of Common Stock upon the exercise of Warrants. If, by reason of any adjustment made pursuant to this Section 4, the
holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company
shall, upon such exercise, round down to the nearest whole number the number of shares of Common Stock to be issued to such holder.

 

4.7 Form
of Warrant. The form of Warrant need not be changed because of any adjustment pursuant to this Section 4, and Warrants
issued after such adjustment may state the same Warrant Price and the same number of shares of Common Stock as is stated in the
Warrants initially issued pursuant to this Agreement; provided, however, that the Company may at any time
in its sole discretion make any change in the form of Warrant that the Company may deem appropriate and that does not affect the
substance thereof, and any Warrant thereafter issued or countersigned, whether in exchange or substitution for an outstanding Warrant
or otherwise, may be in the form as so changed.

 

4.8 Other
Events. In case any event shall occur affecting the Company as to which none of the provisions of preceding subsections of
this Section 4 are strictly applicable, but which would require an adjustment to the terms of the Warrants in
order to (i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of this Section 4,
then, in each such case, the Company shall appoint a firm of independent public accountants, investment banking or other appraisal
firm of recognized national standing, which shall give its opinion as to whether or not any adjustment to the rights represented
by the Warrants is necessary to effectuate the intent and purpose of this Section 4 and, if they determine that
an adjustment is necessary, the terms of such adjustment, provided, however, that under no circumstances shall the Warrants be
adjusted pursuant to this Section 4.8 as a result of any issuance of securities in connection with the Business Combination. The
Company shall adjust the terms of the Warrants in a manner that is consistent with any adjustment recommended in such opinion.

 

4.9 No Adjustment.
For the avoidance of doubt, no adjustment shall be made to the terms of the Warrants solely as a result of an adjustment to the
conversion ratio of the Company’s Class B common stock (the “Class B Common Stock”) into shares
of Common Stock or the conversion of the shares of Class B Common Stock into shares of Common Stock, in each case, pursuant to
the Company’s Charter, as amended from time to time.

 

5. Transfer
and Exchange of Warrants.

 

5.1 Registration
of Transfer. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant upon the Warrant
Register, upon surrender of such Warrant for transfer, in the case of certificated Warrants, properly endorsed with signatures
properly guaranteed and accompanied by appropriate instructions for transfer. Upon any such transfer, a new Warrant representing
an equal aggregate number of Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent. In the case
of certificated Warrants, the Warrants so cancelled shall be delivered by the Warrant Agent to the Company from time to time upon
request.

 

5.2 Procedure
for Surrender of Warrants. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange or
transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered
Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however,
that except as otherwise provided herein or in any Book-Entry Warrant Certificate or Definitive Warrant Certificate, each Book-Entry
Warrant Certificate and Definitive Warrant Certificate may be transferred only in whole and only to the Depositary, to another
nominee of the Depositary, to a successor depository, or to a nominee of a successor depository; provided further, however,
that in the event that a Warrant surrendered for transfer bears a restrictive legend (as in the case of the Private Placement Warrants
and the Working Capital Warrants), the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange thereof until
the Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether
the new Warrants must also bear a restrictive legend.

 

5.3 Fractional
Warrants. The Warrant Agent shall not be required to effect any registration of transfer or exchange which shall result in
the issuance of a warrant certificate or book-entry position for a fraction of a warrant.

 

5.4 Service
Charges. No service charge shall be made for any exchange or registration of transfer of Warrants.

 

     

     

    

 

5.5 Warrant
Execution and Countersignature. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the
terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the Company,
whenever required by the Warrant Agent, shall supply the Warrant Agent with Warrants duly executed on behalf of the Company for
such purpose.

 

5.6 Transfer
of Warrants. Prior to the Detachment Date, the Public Warrants may be transferred or exchanged only together with the Unit
in which such Warrant is included, and only for the purpose of effecting, or in conjunction with, a transfer or exchange of such
Unit. Furthermore, each transfer of a Unit on the register relating to such Units shall operate also to transfer the Warrants included
in such Unit. Notwithstanding the foregoing, the provisions of this Section 5.6 shall have no effect on any transfer
of Warrants on and after the Detachment Date.

  

6. Redemption.

 

6.1 Redemption.
Subject to Section 6.4 hereof, not less than all of the outstanding Warrants may be redeemed, at the option of
the Company, at any time while they are exercisable and prior to their expiration, at the office of the Warrant Agent, upon notice
to the Registered Holders of the Warrants, as described in Section 6.2 below, at the price of $0.01 per Warrant
(the “Redemption Price”), provided that the last sales price of the Common Stock reported has been
at least $18.00 per share (subject to adjustment in compliance with Section 4 hereof) (the “Redemption
Trigger Price”), on each of twenty (20) trading days within the thirty (30) trading-day period ending on the third
Business Day prior to the date on which notice of the redemption is given and provided that there is an effective registration
statement covering the shares of Common Stock issuable upon exercise of the Warrants, and a current prospectus relating thereto,
available throughout the 30-day Redemption Period (as defined in Section 6.2 below) or the Company has elected
to require the exercise of the Warrants on a “cashless basis” pursuant to subsection 3.3.1; provided, however,
that if and when the Public Warrants become redeemable by the Company, the Company may not exercise such redemption right if the
issuance of shares of Common Stock upon exercise of the Public Warrants is not exempt from registration or qualification under
applicable state blue sky laws or the Company is unable to effect such registration or qualification.

 

6.2 Date
Fixed for, and Notice of, Redemption. In the event that the Company elects to redeem all of the Warrants, the Company shall
fix a date for the redemption (the “Redemption Date”). Notice of redemption shall be mailed by first
class mail, postage prepaid, by the Company not less than thirty (30) days prior to the Redemption Date (the “30-day
Redemption Period”) to the Registered Holders of the Warrants to be redeemed at their last addresses as they shall
appear on the registration books. Any notice mailed in the manner herein provided shall be conclusively presumed to have been duly
given whether or not the Registered Holder received such notice.

 

6.3 Exercise
After Notice of Redemption. The Warrants may be exercised, for cash (or on a “cashless basis” in accordance with subsection
3.3.1(b) of this Agreement) at any time after notice of redemption shall have been given by the Company pursuant to Section
6.2 hereof and prior to the Redemption Date. In the event that the Company determines to require all holders of Warrants
to exercise their Warrants on a “cashless basis” pursuant to subsection 3.3.1, the notice of redemption
shall contain the information necessary to calculate the number of shares of Common Stock to be received upon exercise of the Warrants,
including the “Fair Market Value” (as such term is defined in subsection 3.3.1(b) hereof) in such
case. On and after the Redemption Date, the record holder of the Warrants shall have no further rights except to receive, upon
surrender of the Warrants, the Redemption Price.

 

6.4 Exclusion
of Private Placement Warrants and Working Capital Warrants. The Company agrees that the redemption rights provided in this Section
6 shall not apply to the Private Placement Warrants or the Working Capital Warrants if at the time of the redemption such
Private Placement Warrants or the Working Capital Warrants continue to be held by a Subscriber or any Permitted Transferees, as
applicable. However, once such Private Placement Warrants or Working Capital Warrants are transferred (other than to Permitted
Transferees under Section 2.6), the Company may redeem the Private Placement Warrants and the Working Capital Warrants,
provided that the criteria for redemption are met, including the opportunity of the holder of such Private Placement Warrants or
the Working Capital Warrants to exercise the Private Placement Warrants and the Working Capital Warrants prior to redemption pursuant
to Section 6.3. Private Placement Warrants and Working Capital Warrants that are transferred to persons other than
Permitted Transferees shall upon such transfer cease to be Private Placement Warrants or Working Capital Warrants and shall become
Public Warrants under this Agreement.

 

     

     

    

  

7. Other Provisions
Relating to Rights of Holders of Warrants.

 

7.1 No Rights
as Stockholder. A Warrant does not entitle the Registered Holder thereof to any of the rights of a stockholder of the Company,
including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote or
to consent or to receive notice as stockholders in respect of the meetings of stockholders or the election of directors of the
Company or any other matter.

 

7.2 Lost,
Stolen, Mutilated, or Destroyed Warrants. If any Warrant is lost, stolen, mutilated, or destroyed, the Company and the Warrant
Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a mutilated
Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor, and date as the Warrant so lost, stolen,
mutilated, or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not
the allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by anyone.

 

7.3 Reservation
of Common Stock. The Company shall at all times reserve and keep available a number of its authorized but unissued shares of
Common Stock that shall be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.

 

7.4 Registration
of Common Stock; Cashless Exercise at Company’s Option.

 

7.4.1 Registration
of the Common Stock. The Company agrees that as soon as practicable, but in no event later than fifteen (15) Business Days
after the closing of its initial Business Combination, it shall use its best efforts to file with the Commission a registration
statement for the registration, under the Securities Act, of the shares of Common Stock issuable upon exercise of the Warrants.
The Company shall use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration
statement, and a current prospectus relating thereto, until the expiration of the Warrants in accordance with the provisions of
this Agreement. If any such registration statement has not been declared effective by the 60th Business Day following the closing
of the Business Combination, holders of the Warrants shall have the right, during the period beginning on the 61st Business Day
after the closing of the Business Combination and ending upon such registration statement being declared effective by the Commission,
and during any other period when the Company shall fail to have maintained an effective registration statement covering the shares
of Common Stock issuable upon exercise of the Warrants, to exercise such Warrants on a “cashless basis,” by exchanging
the Warrants (in accordance with Section 3(a)(9) of the Securities Act (or any successor rule) or another exemption) for that number
of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying
the Warrants, multiplied by the difference between the Warrant Price and the “Fair Market Value” (as defined below)
by (y) the Fair Market Value. Solely for purposes of this subsection 7.4.1, “Fair Market Value” shall mean
the volume weighted average price of the Common Stock as reported during the ten (10) trading day period ending on the trading
day prior to the date that notice of exercise is received by the Warrant Agent from the holder of such Warrants or its securities
broker or intermediary. The date that notice of cashless exercise is received by the Warrant Agent shall be conclusively determined
by the Warrant Agent. In connection with the “cashless exercise” of a Public Warrant, the Company shall, upon request,
provide the Warrant Agent with an opinion of counsel for the Company (which shall be an outside law firm with securities law experience)
stating that (i) the exercise of the Warrants on a cashless basis in accordance with this subsection 7.4.1 is
not required to be registered under the Securities Act and (ii) the shares of Common Stock issued upon such exercise shall be freely
tradable under United States federal securities laws by anyone who is not an affiliate (as such term is defined in Rule 144 under
the Securities Act (or any successor statute)) of the Company and, accordingly, shall not be required to bear a restrictive legend.
Except as provided in subsection 7.4.2, for the avoidance of any doubt, unless and until all of the Warrants have been
exercised or have expired, the Company shall continue to be obligated to comply with its registration obligations under the first
three sentences of this subsection 7.4.1.

 

7.4.2 Cashless
Exercise at Company’s Option. If the Common Stock is at the time of any exercise of a Warrant not listed on a
national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1)
of the Securities Act (or any successor statute), the Company may, at its option, (i) require holders of Public Warrants who
exercise Public Warrants to exercise such Public Warrants on a “cashless basis” in accordance with Section
3(a)(9) of the Securities Act (or any successor statute) as described in subsection 7.4.1 and (ii) in the
event the Company so elects, the Company shall not be required to file or maintain in effect a registration statement for the
registration, under the Securities Act, of the Common Stock issuable upon exercise of the Warrants, notwithstanding anything
in this Agreement to the contrary. If the Company does not elect at the time of exercise to require a holder of Public
Warrants who exercises Public Warrants to exercise such Public Warrants on a “cashless basis,” it agrees to use
its best efforts to register or qualify for sale the Common Stock issuable upon exercise of the Public Warrant under the blue
sky laws of the state of residence of the exercising Public Warrant holder to the extent an exemption is not available.

 

     

     

    

 

8. Concerning
the Warrant Agent and Other Matters.

 

8.1 Payment
of Taxes. The Company shall from time to time promptly pay all taxes and charges that may be imposed upon the Company or the
Warrant Agent in respect of the issuance or delivery of shares of Common Stock upon the exercise of the Warrants, but the Company
shall not be obligated to pay any transfer taxes in respect of the Warrants or such shares of Common Stock.

 

8.2 Resignation,
Consolidation, or Merger of Warrant Agent.

 

8.2.1 Appointment
of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged
from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the
office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing
a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of
thirty (30) days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder
of a Warrant (who shall, with such notice, submit his Warrant for inspection by the Company), then the holder of any Warrant may
apply to the Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent
at the Company’s cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation
organized and existing under the laws of the State of New York, in good standing and having its principal office in the Borough
of Manhattan, City and State of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision
or examination by federal or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority,
powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as
Warrant Agent hereunder, without any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor
Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent
all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent
the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting
in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.

  

8.2.2 Notice
of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof
to the predecessor Warrant Agent and the Transfer Agent for the Common Stock not later than the effective date of any such appointment.

 

8.2.3 Merger
or Consolidation of Warrant Agent. Any corporation into which the Warrant Agent may be merged or with which it may be consolidated
or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor
Warrant Agent under this Agreement without any further act.

 

8.3 Fees
and Expenses of Warrant Agent.

 

8.3.1 Remuneration.
The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder and shall,
pursuant to its obligations under this Agreement, reimburse the Warrant Agent upon demand for all expenditures that the Warrant
Agent may reasonably incur in the execution of its duties hereunder.

 

8.3.2 Further
Assurances. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed,
acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the
Warrant Agent for the carrying out or performing of the provisions of this Agreement.

 

     

     

    

 

8.4 Liability
of Warrant Agent.

 

8.4.1 Reliance
on Company Statement. Whenever in the performance of its duties under this Agreement, the Warrant Agent shall deem it necessary
or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder,
such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively
proved and established by a statement signed by the Chief Executive Officer, Chief Financial Officer, President, Executive Vice
President, Vice President, Secretary or Chairman of the Board of the Company and delivered to the Warrant Agent. The Warrant Agent
may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.

 

8.4.2 Indemnity.
The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. The Company agrees
to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable
counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except as a result of the Warrant
Agent’s gross negligence, willful misconduct or bad faith.

 

8.4.3 Exclusions.
The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity or
execution of any Warrant (except its countersignature thereof). The Warrant Agent shall not be responsible for any breach by the
Company of any covenant or condition contained in this Agreement or in any Warrant. The Warrant Agent shall not be responsible
to make any adjustments required under the provisions of Section 4 hereof or responsible for the manner, method,
or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor shall
it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of
Common Stock to be issued pursuant to this Agreement or any Warrant or as to whether any shares of Common Stock shall, when issued,
be valid and fully paid and non-assessable.

 

8.5 Acceptance
of Agency. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the
terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to Warrants exercised
and concurrently account for, and pay to the Company, all monies received by the Warrant Agent for the purchase of shares of Common
Stock through the exercise of the Warrants.

 

8.6 Waiver.
The Warrant Agent has no right of set-off or any other right, title, interest or claim of any kind (“Claim”)
in, or to any distribution of, the Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of
the date hereof, by and between the Company and the Warrant Agent as trustee thereunder) and hereby agrees not to seek recourse,
reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever. The Warrant Agent hereby
waives any and all Claims against the Trust Account and any and all rights to seek access to the Trust Account.

 

9. Miscellaneous
Provisions.

 

9.1 Successors.
All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure
to the benefit of their respective successors and assigns.

 

     

     

    

 

9.2 Notices.
Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the holder of any Warrant
to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail
or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address
is filed in writing by the Company with the Warrant Agent), as follows:

 

Growth Capital Acquisition Corp.

The Chrysler Building

405 Lexington Ave

New York, NY 10174

Attention: Prokopios Tsirigakis

 

Any notice, statement or demand authorized
by this Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be sufficiently
given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five (5)
days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Warrant Agent with
the Company), as follows:

 

Continental Stock Transfer & Trust
Company

1 State Street, 30th Floor

New York, NY 10004

Attention: Compliance Department

 

9.3 Applicable
Law. The validity, interpretation, and performance of this Agreement and of the Warrants shall be governed in all respects
by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application
of the substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim against it arising
out of or relating in any way to this Agreement (including, but not limited to, claims brought to enforce any liability or duty
created by the Securities Act) shall be brought and enforced in the courts of the State of New York or the United States District
Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive
forum for any such action, proceeding or claim. The Company hereby waives any objection to such exclusive jurisdiction and that
such courts represent an inconvenient forum. Notwithstanding the foregoing, the provisions of this paragraph will not apply to
suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts
of the United States of America are the sole and exclusive forum.

 

Any person or entity
purchasing or otherwise acquiring any interest in the Warrants shall be deemed to have notice of and to have consented to the forum
provisions in this Section 9.3. If any action, the subject matter of which is within the scope the forum provisions above, is filed
in a court other than a court located within the State of New York or the United States District Court for the Southern District
of New York (a “foreign action”) in the name of any warrant holder, such warrant holder shall be deemed to have consented
to: (x) the personal jurisdiction of the state and federal courts located within the State of New York or the United States District
Court for the Southern District of New York in connection with any action brought in any such court to enforce the forum provisions
(an “enforcement action”), and (y) having service of process made upon such warrant holder in any such enforcement
action by service upon such warrant holder’s counsel in the foreign action as agent for such warrant holder.

 

9.4 Persons
Having Rights under this Agreement. Nothing in this Agreement shall be construed to confer upon, or give to, any person or
corporation other than the parties hereto and the Registered Holders of the Warrants, any right, remedy, or claim under or by reason
of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. All covenants, conditions, stipulations,
promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their
successors and assigns and of the Registered Holders of the Warrants.

 

9.5 Examination
of the Warrant Agreement. A copy of this Agreement shall be available at all reasonable times at the office of the Warrant
Agent in the Borough of Manhattan, City and State of New York, for inspection by the Registered Holder of any Warrant. The Warrant
Agent may require any such holder to submit such holder’s Warrant for inspection by the Warrant Agent.

 

 

9.6 Counterparts.
This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all
purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

9.7 Effect
of Headings. The section headings herein are for convenience only and are not part of this Agreement and shall not affect the
interpretation thereof.

 

     

     

    

 

9.8 Amendments.
This Agreement may be amended by the parties hereto without the consent of any Registered Holder (i) for the purpose of curing
any ambiguity, or curing, correcting or supplementing any defective provision contained herein or adding or changing any other
provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and
that the parties deem shall not adversely affect the interest of the Registered Holders, and (ii) to provide for the delivery of
Alternative Issuance pursuant to Section 4.4. All other modifications or amendments, including any amendment to increase the Warrant
Price or shorten the Exercise Period, shall require the vote or written consent of the Registered Holders of a majority of the
then outstanding Public Warrants. Any amendment solely to the Private Placement Warrants or the Working Capital Warrants shall
require the vote or written consent of a majority of the holders of the then outstanding Private Placement Warrants or the Working
Capital Warrants. Notwithstanding the foregoing, the Company may lower the Warrant Price or extend the duration of the Exercise
Period pursuant to Sections 3.1 and 3.2, respectively, without the consent of the Registered Holders.

 

9.9 Severability.
This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect
the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid
or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision
as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

[Signature Page Follows]

 

     

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be duly executed as of the date first above written.

 

	 	GROWTH CAPITAL ACQUISITION CORP.
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 	 
	 	CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Warrant Agent
	 	 
	 	By:	                         
	 	Name:     	 
	 	Title:	 

 

     

     

    

 

EXHIBIT A

 

[Form of Warrant Certificate]

 

[FACE]

 

Number

 

Warrants

 

THIS WARRANT SHALL BE VOID IF NOT EXERCISED
PRIOR TO

THE EXPIRATION OF THE EXERCISE PERIOD
PROVIDED FOR

IN THE WARRANT AGREEMENT DESCRIBED BELOW

 

GROWTH CAPITAL ACQUISITION CORP.

Incorporated Under the
Laws of the State of Delaware

 

CUSIP 39986V 115

 

Warrant Certificate

 

This Warrant
Certificate certifies that               , or
registered assigns, is the registered holder of warrant(s) evidenced hereby (the “Warrants” and each,
a “Warrant”) to purchase shares of Class A common stock, $0.0001 par value per share (“Common Stock”),
of Growth Capital Acquisition Corp., a Delaware corporation (the “Company”). Each whole Warrant entitles
the holder, upon exercise during the period set forth in the Warrant Agreement referred to below, to receive from the Company that
number of fully paid and non-assessable shares of Common Stock as set forth below, at the exercise price (the “Exercise
Price”) as determined pursuant to the Warrant Agreement, payable in lawful money (or through “cashless
exercise” as provided for in the Warrant Agreement) of the United States of America upon surrender of this Warrant
Certificate and payment of the Exercise Price at the office or agency of the Warrant Agent referred to below, subject to the conditions
set forth herein and in the Warrant Agreement. Defined terms used in this Warrant Certificate but not defined herein shall have
the meanings given to them in the Warrant Agreement.

 

Each whole Warrant
is initially exercisable for one fully paid and non-assessable share of Common Stock. No fractional shares will be issued upon
exercise of any Warrant. If, upon the exercise of Warrants, a holder would be entitled to receive a fractional interest in a share
of Common Stock, the Company will, upon exercise, round down to the nearest whole number the number of shares of Common Stock to
be issued to the Warrant holder. The number of shares of Common Stock issuable upon exercise of the Warrants is subject to adjustment
upon the occurrence of certain events set forth in the Warrant Agreement.

 

The initial Exercise
Price per share of Common Stock for any Warrant is equal to $11.50 per share. The Exercise Price is subject to adjustment upon
the occurrence of certain events set forth in the Warrant Agreement.

 

Subject to the conditions
set forth in the Warrant Agreement, the Warrants may be exercised only during the Exercise Period and to the extent not exercised
by the end of such Exercise Period, such Warrants shall become void. The Warrants may be redeemed, subject to certain conditions,
as set forth in the Warrant Agreement.

 

Reference is hereby
made to the further provisions of this Warrant Certificate set forth on the reverse hereof and such further provisions shall for
all purposes have the same effect as though fully set forth at this place.

 

This Warrant Certificate
shall not be valid unless countersigned by the Warrant Agent, as such term is used in the Warrant Agreement.

 

This Warrant Certificate
shall be governed by and construed in accordance with the internal laws of the State of New York, without regard to conflicts of
laws principles thereof.

 

     

     

    

 

	 	GROWTH CAPITAL ACQUISITION CORP.
	 	 	 
	 	By:	                          
	 	Name:    	 
	 	Title:	 
	 	 	 
	 	CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Warrant Agent
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

     

     

    

 

[Form of Warrant Certificate]

 

[Reverse]

 

The Warrants evidenced
by this Warrant Certificate are part of a duly authorized issue of Warrants entitling the holder on exercise to receive shares
of Common Stock and are issued or to be issued pursuant to a Warrant Agreement dated as of                ,
2021 (the “Warrant Agreement”), duly executed and delivered by the Company to Continental Stock Transfer
 & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”), which Warrant Agreement
is hereby incorporated by reference in and made a part of this instrument and is hereby referred to for a description of the rights,
limitation of rights, obligations, duties and immunities thereunder of the Warrant Agent, the Company and the holders (the words
 “holders” or “holder” meaning the Registered Holders or Registered Holder,
respectively) of the Warrants. A copy of the Warrant Agreement may be obtained by the holder hereof upon written request to the
Company. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant
Agreement.

 

Warrants may be exercised
at any time during the Exercise Period set forth in the Warrant Agreement. The holder of Warrants evidenced by this Warrant Certificate
may exercise them by surrendering this Warrant Certificate, with the form of election to purchase set forth hereon properly completed
and executed, together with payment of the Exercise Price as specified in the Warrant Agreement (or through “cashless exercise”
as provided for in the Warrant Agreement) at the principal corporate trust office of the Warrant Agent. In the event that upon
any exercise of Warrants evidenced hereby the number of Warrants exercised shall be less than the total number of Warrants evidenced
hereby, there shall be issued to the holder hereof or his, her or its assignee, a new Warrant Certificate evidencing the number
of Warrants not exercised.

 

Notwithstanding anything
else in this Warrant Certificate or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise (i) a registration
statement covering the shares of Common Stock to be issued upon exercise is effective under the Securities Act and (ii) a prospectus
thereunder relating to the shares of Common Stock is current, except through “cashless exercise” as provided for in
the Warrant Agreement.

 

The Warrant Agreement
provides that upon the occurrence of certain events the number of shares of Common Stock issuable upon exercise of the Warrants
set forth on the face hereof may, subject to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder thereof
would be entitled to receive a fractional interest in a share of Common Stock, the Company shall, upon exercise, round down to
the nearest whole number of shares of Common Stock to be issued to the holder of the Warrant.

 

Warrant Certificates,
when surrendered at the principal corporate trust office of the Warrant Agent by the Registered Holder thereof in person or by
legal representative or attorney duly authorized in writing, may be exchanged, in the manner and subject to the limitations provided
in the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant Certificates of
like tenor evidencing in the aggregate a like number of Warrants.

 

Upon due presentation
for registration of transfer of this Warrant Certificate at the office of the Warrant Agent a new Warrant Certificate or Warrant
Certificates of like tenor and evidencing in the aggregate a like number of Warrants shall be issued to the transferee(s) in exchange
for this Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without charge except for any tax or
other governmental charge imposed in connection therewith.

 

The Company and the
Warrant Agent may deem and treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant Certificate (notwithstanding
any notation of ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution
to the holder(s) hereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice
to the contrary. Neither the Warrants nor this Warrant Certificate entitles any holder hereof to any rights of a stockholder of
the Company.

 

     

     

    

 

Election to Purchase

 

(To Be Executed Upon Exercise of Warrant)

 

Reference is
hereby made to the warrant (Warrant”) of Growth Capital Acquisition Corp. (the “Company”), a
Delaware corporation, registered in book entry form in the name of [the undersigned] entitling the holder to purchase shares
of common stock (“Commom Stock”) of Growth Capital Acquisition Corp. (the “Issuer”). The Warrant
consists of warrants of the Issuer.

 

The undersigned hereby
irrevocably elects to exercise the right, to receive shares of Common Stock pursuant to the exercise in full of the Warrant and
herewith tenders payment for such shares of Common Stock to the order of Growth Capital Acquisition Corp. (the “Company”)
in the amount of $        in accordance with the terms hereof. The undersigned requests that
a certificate for such shares of Common Stock be registered in book entry form in the name of             ,
whose address is                   .
If said number of shares of Common Stock is less than all of the shares of Common Stock purchasable hereunder, the undersigned
requests that a new Warrant Certificate representing the remaining balance of such shares of Common Stock be registered in the
name of              , whose address is               .

 

In the event that
the Warrant has been called for redemption by the Company pursuant to Section 6 of the Warrant Agreement and the
Company has required cashless exercise pursuant to Section 6.3 of the Warrant Agreement, the number of shares
of Common Stock that this Warrant is exercisable for shall be determined in accordance with subsection 3.3.1(b) and Section
6.3 of the Warrant Agreement.

 

In the event that
the Warrant is a Private Placement Warrant, Working Capital Warrant or Post-IPO Warrant that is to be exercised on a “cashless”
basis pursuant to subsection 3.3.1(c) of the Warrant Agreement, the number of shares of Common Stock that this
Warrant is exercisable for shall be determined in accordance with subsection 3.3.1(c) of the Warrant Agreement.

 

In the event that
the Warrant is to be exercised on a “cashless” basis pursuant to Section 7.4 of the Warrant Agreement,
the number of shares of Common Stock that this Warrant is exercisable for shall be determined in accordance with Section
7.4 of the Warrant Agreement.

 

In the event that
the Warrant may be exercised, to the extent allowed by the Warrant Agreement, through cashless exercise (i) the number of shares
of Common Stock that this Warrant is exercisable for would be determined in accordance with the relevant section of the Warrant
Agreement which allows for such cashless exercise and (ii) the holder hereof shall complete the following: The undersigned hereby
irrevocably elects to exercise the right, represented by this Warrant Certificate, through the cashless exercise provisions of
the Warrant Agreement, to receive shares of Common Stock. If said number of shares of Common Stock is less than all of the shares
of Common Stock purchasable hereunder (after giving effect to the cashless exercise), the undersigned requests that a new Warrant
Certificate representing the remaining balance of such shares of Common Stock be registered in the name of               ,
whose address is                and that such Warrant
Certificate be delivered to              , whose address is                    .

 

[Signature Page Follows]

 

	Date:                      , 20	 
	 	(Signature)
	 	 
	 	 
	 	 
	 	 
	 	(Address)
	 	 
	 	 
	 	(Tax Identification Number)
	 	 
	Signature Guaranteed:	 
	 	 

 

	 	 

 

THE SIGNATURE(S) SHOULD BE GUARANTEED BY
AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED
SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 (OR ANY SUCCESSOR RULE)).

 

     

     

    

 

EXHIBIT B

 

LEGEND

 

“THE SECURITIES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE
OFFERED, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE
STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT TO ANY ADDITIONAL LIMITATIONS ON TRANSFER
DESCRIBED IN THE LETTER AGREEMENT BY AND AMONG GROWTH CAPITAL ACQUISITION CORP. (THE “COMPANY”), GROWTH CAPITAL SPONSOR
LLC AND THE OTHER PARTIES THERETO, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE DATE
THAT IS THIRTY (30) DAYS AFTER THE DATE UPON WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN SECTION
3 OF THE WARRANT AGREEMENT REFERRED TO HEREIN) EXCEPT TO A PERMITTED TRANSFEREE (AS DEFINED IN SECTION 2 OF THE WARRANT AGREEMENT)
WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS.

 

SECURITIES EVIDENCED BY THIS CERTIFICATE
AND SHARES OF CLASS A COMMON STOCK OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO REGISTRATION RIGHTS
UNDER A REGISTRATION RIGHTS AGREEMENT TO BE EXECUTED BY THE COMPANY.”

 

    B-1

     

    

 

EXHIBIT C

 

LEGEND

 

“THE SECURITIES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT
BE OFFERED, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY
APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT TO ANY ADDITIONAL LIMITATIONS
ON TRANSFER DESCRIBED IN THE PRIVATE PLACEMENT WARRANTS SUBSCRIPTION AGREEMENT BY AND BETWEEN GROWTH CAPITAL ACQUISITION CORP.
(THE “COMPANY”) AND [________], THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED
PRIOR TO THE DATE THAT IS THIRTY (30) DAYS AFTER THE DATE UPON WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION
(AS DEFINED IN SECTION 3 OF THE WARRANT AGREEMENT REFERRED TO HEREIN) EXCEPT TO A PERMITTED TRANSFEREE (AS DEFINED IN SECTION 2
OF THE WARRANT AGREEMENT) WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS.

 

SECURITIES EVIDENCED BY THIS CERTIFICATE
AND SHARES OF CLASS A COMMON STOCK OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO REGISTRATION
RIGHTS UNDER A REGISTRATION RIGHTS AGREEMENT TO BE EXECUTED BY THE COMPANY.”

 

    C-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]